TGF-β signalling and liver disease

FEBS Journal

Volumn , Issue , 2016, Pages 2219-2232

  Fabregat, Isabel ^a,b   Moreno Càceres, Joaquim ^a   Sánchez, Aránzazu ^c   Dooley, Steven ^d   Dewidar, Bedair ^d,e   Giannelli, Gianluigi ^f   ten Dijke, Peter ^g  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e TANTA UNIVERSITY   (Egypt)

^f UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^g Cancer Genomics Centre Netherlands   (Netherlands)

Author keywords

chronic liver injury; development; fibrosis; hepatocarcinogenesis; hepatocellular carcinoma; inflammation; liver; regeneration; signalling; TGF beta

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DISEASE COURSE; HOMEOSTASIS; HUMAN; LIVER CARCINOGENESIS; LIVER DISEASE; LIVER FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84976487656     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13665     Document Type: Article

References (103)

1. Dooley S & ten Dijke P (2012) TGF-beta in progression of liver disease. Cell Tissue Res 347, 245–256.
2. Karkampouna S, Ten Dijke P, Dooley S & Julio MK (2012) TGF-beta signaling in liver regeneration. Curr Pharm Des 18, 4103–4113.
3. Meindl-Beinker NM, Matsuzaki K & Dooley S (2012) TGF-beta signaling in onset and progression of hepatocellular carcinoma. Dig Dis 30, 514–523.
4. Massague J (2008) TGFbeta in Cancer. Cell 134, 215–230.
5. Giannelli G, Rani B, Dituri F, Cao Y & Palasciano G (2014) Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 63, 1668–1676.
6. Fabregat I, Fernando J, Mainez J & Sancho P (2014) TGF-beta signaling in cancer treatment. Curr Pharm Des 20, 2934–2947.
7. Massague J (2012) TGF-beta signalling in context. Nat Rev Mol Cell Biol 13, 616–630.
8. Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, Cao W, Bots SJ, Kodach LL, de Man RA et al. (2015) SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene 34, 5055–5068.
9. Palumbo-Zerr K, Zerr P, Distler A, Fliehr J, Mancuso R, Huang J, Mielenz D, Tomcik M, Furnrohr BG, Scholtysek C et al. (2015) Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis. Nat Med 21, 150–158.
10. Martin M, Ancey PB, Cros MP, Durand G, Le Calvez-Kelm F, Hernandez-Vargas H & Herceg Z (2014) Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-beta) is associated with a DNA methylome switch. BMC Genom 15, 435.
11. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC et al. (2014) A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25, 666–681.
12. Zeng C, Wang YL, Xie C, Sang Y, Li TJ, Zhang M, Wang R, Zhang Q, Zheng L, Zhuang SM (2015) Identification of a novel TGF-beta-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis. Oncotarget 6, 12224–12233.
13. Dahl M, Maturi V, Lonn P, Papoutsoglou P, Zieba A, Vanlandewijck M, van der Heide LP, Watanabe Y, Soderberg O, Hottiger MO et al. (2014) Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and poly(ADP-ribose) glycohydrolase during transforming growth factor beta signaling. PLoS One 9, e103651.
14. Matsuzaki K (2013) Smad phospho-isoforms direct context-dependent TGF-beta signaling. Cytokine Growth Factor Rev 24, 385–399.
15. Yoshida K, Murata M, Yamaguchi T & Matsuzaki K (2014) TGF-beta/Smad signaling during hepatic fibro-carcinogenesis (review). Int J Oncol 45, 1363–1371.
16. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M & Mikulits W (2015) Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. Hepatology 61, 930–941.
17. Moustakas A & Heldin CH (2005) Non-Smad TGF-beta signals. J Cell Sci 118, 3573–3584.
18. Zhang YE (2009) Non-Smad pathways in TGF-beta signaling. Cell Res 19, 128–139.
19. Hedger MP & de Kretser DM (2013) The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev 24, 285–295.
20. Herrera B, Garcia-Alvaro M, Cruz S, Walsh P, Fernandez M, Roncero C, Fabregat I, Sanchez A & Inman GJ (2013) BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PLoS ONE 8, e69535.
21. Garcia-Alvaro M, Addante A, Roncero C, Fernandez M, Fabregat I, Sanchez A & Herrera B (2015) BMP9-Induced Survival Effect in Liver Tumor Cells Requires p38MAPK Activation. Int J Mol Sci 16, 20431–20448.
22. Weinstein M, Monga SP, Liu Y, Brodie SG, Tang Y, Li C, Mishra L & Deng CX (2001) Smad proteins and hepatocyte growth factor control parallel regulatory pathways that converge on beta1-integrin to promote normal liver development. Mol Cell Biol 21, 5122–5131.
23. Ader T, Norel R, Levoci L & Rogler LE (2006) Transcriptional profiling implicates TGF-beta/BMP and Notch signaling pathways in ductular differentiation of fetal murine hepatoblasts. Mech Dev 123, 177–194.
24. Rogler CE, Levoci L, Ader T, Massimi A, Tchaikovskaya T, Norel R & Rogler LE (2009) MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. Hepatology 50, 575–584.
25. Wei W, Hou J, Alder O, Ye X, Lee S, Cullum R, Chu A, Zhao Y, Warner SM, Knight DA et al. (2013) Genome-wide microRNA and messenger RNA profiling in rodent liver development implicates mir302b and mir20a in repressing transforming growth factor-beta signaling. Hepatology 57, 2491–2501.
26. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, Jacquemin P, Pierreux CE, Clotman F & Lemaigre FP (2009) Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 136, 2325–2333.
27. Poncy A, Antoniou A, Cordi S, Pierreux CE, Jacquemin P & Lemaigre FP (2015) Transcription factors SOX4 and SOX9 cooperatively control development of bile ducts. Dev Biol 404, 136–148.
28. Paganelli M, Nyabi O, Sid B, Evraerts J, El Malmi I, Heremans Y, Dolle L, Benton C, Calderon PB, van Grunsven L et al. (2014) Downregulation of SOX9 expression associates with hepatogenic differentiation of human liver mesenchymal stem/progenitor cells. Stem Cells Dev 23, 1377–1391.
29. Herrera B, Alvarez AM, Beltran J, Valdes F, Fabregat I & Fernandez M (2004) Resistance to TGF-beta-induced apoptosis in regenerating hepatocytes. J Cell Physiol 201, 385–392.
30. Yuan B, Dong R, Shi D, Zhou Y, Zhao Y, Miao M & Jiao B (2011) Down-regulation of miR-23b may contribute to activation of the TGF-beta1/Smad3 signalling pathway during the termination stage of liver regeneration. FEBS Lett 585, 927–934.
31. Hu J, Srivastava K, Wieland M, Runge A, Mogler C, Besemfelder E, Terhardt D, Vogel MJ, Cao L, Korn C et al. (2014) Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. Science 343, 416–419.
32. Crosas-Molist E, Bertran E, Sancho P, Lopez-Luque J, Fernando J, Sanchez A, Fernandez M, Navarro E & Fabregat I (2014) The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression. Free Radic Biol Med 69, 338–347.
33. Lopez-Luque J, Caballero-Diaz D, Martinez-Palacian A, Roncero C, Moreno-Caceres J, Garcia-Bravo M, Grueso E, Fernandez A, Crosas-Molist E, Garcia-Alvaro M et al. (2016) Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology 63, 604–619.
34. Revuelta-Cervantes J, Mayoral R, Miranda S, Gonzalez-Rodriguez A, Fernandez M, Martin-Sanz P & Valverde AM (2011) Protein Tyrosine Phosphatase 1B (PTP1B) deficiency accelerates hepatic regeneration in mice. Am J Pathol 178, 1591–1604.
35. Ortiz C, Caja L, Bertran E, Gonzalez-Rodriguez A, Valverde AM, Fabregat I & Sancho P (2012) Protein-tyrosine phosphatase 1B (PTP1B) deficiency confers resistance to transforming growth factor-beta (TGF-beta)-induced suppressor effects in hepatocytes. J Biol Chem 287, 15263–15274.
36. Edelmann S, Fahrner R, Malinka T, Song BH, Stroka D & Mermod N (2015) Nuclear Factor I-C acts as a regulator of hepatocyte proliferation at the onset of liver regeneration. Liver Int 35, 1185–1194.
37. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernandez M, Benito M, Nieto MA & Fabregat I (2002) The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 1, 68–78.
38. Zhao S, Zhang Y, Zheng X, Tu X, Li H, Chen J, Zang Y & Zhang J (2015) Loss of MicroRNA-101 promotes epithelial to mesenchymal transition in hepatocytes. J Cell Physiol 230, 2706–2717.
39. Murillo MM, del Castillo G, Sanchez A, Fernandez M & Fabregat I (2005) Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 24, 4580–4587.
40. Kang M, Choi S, Jeong SJ, Lee SA, Kwak TK, Kim H, Jung O, Lee MS, Ko Y, Ryu J et al. (2012) Cross-talk between TGFbeta1 and EGFR signalling pathways induces TM4SF5 expression and epithelial-mesenchymal transition. Biochem J 443, 691–700.
41. Wang P, Yang AT, Cong M, Liu TH, Zhang D, Huang J, Tong XF, Zhu ST, Xu Y, Tang SZ et al. (2015) EGF suppresses the initiation and drives the reversion of TGF-beta1-induced transition in hepatic oval cells showing the plasticity of progenitor cells. J Cell Physiol 230, 2362–2370.
42. Dewidar D, Soukupova J, Fabregat I & Dooley S (2015) TGF-β in hepatic stellate cell activation and liver fibrogenesis: updated. Current Pathobiology Reports 3, 291–305.
43. Sancho P, Mainez J, Crosas-Molist E, Roncero C, Fernandez-Rodriguez CM, Pinedo F, Huber H, Eferl R, Mikulits W & Fabregat I (2012) NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One 7, e45285.
44. Liu Y, Liu H, Meyer C, Li J, Nadalin S, Konigsrainer A, Weng H, Dooley S & ten Dijke P (2013) Transforming growth factor-beta (TGF-beta)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J Biol Chem 288, 30708–30719.
45. Ding ZY, Jin GN, Liang HF, Wang W, Chen WX, Datta PK, Zhang MZ, Zhang B & Chen XP (2013) Transforming growth factor beta induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling. Cell Signal 25, 1981–1992.
46. Li L, Wang JY, Yang CQ & Jiang W (2012) Effect of RhoA on transforming growth factor beta1-induced rat hepatic stellate cell migration. Liver Int 32, 1093–1102.
47. Shah R, Reyes-Gordillo K, Arellanes-Robledo J, Lechuga CG, Hernandez-Nazara Z, Cotty A, Rojkind M & Lakshman MR (2013) TGF-beta1 up-regulates the expression of PDGF-beta receptor mRNA and induces a delayed PI3K-, AKT-, and p70(S6K) -dependent proliferative response in activated hepatic stellate cells. Alcohol Clin Exp Res 37, 1838–1848.
48. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M et al. (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53, 209–218.
49. Roy S, Benz F, Vargas Cardenas D, Vucur M, Gautheron J, Schneider A, Hellerbrand C, Pottier N, Alder J, Tacke F et al. (2015) miR-30c and miR-193 are a part of the TGF-beta-dependent regulatory network controlling extracellular matrix genes in liver fibrosis. J Dig Dis 16, 513–524.
50. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A et al. (2008) Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 135, 642–659.
51. Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R & Seki E (2014) Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 59, 483–495.
52. Tu K, Li J, Verma VK, Liu C, Billadeau DD, Lamprecht G, Xiang X, Guo L, Dhanasekaran R, Roberts LR et al. (2014) Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors. Hepatology 61, 361–374.
53. Liu C, Li J, Xiang X, Guo L, Tu K, Liu Q, Shah VH & Kang N (2014) PDGF receptor-alpha promotes TGF-beta signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-beta receptors. Am J Physiol Gastrointest Liver Physiol 307, G749–G759.
54. Nyati S, Schinske-Sebolt K, Pitchiaya S, Chekhovskiy K, Chator A, Chaudhry N, Dosch J, Van Dort ME, Varambally S, Kumar-Sinha C et al. (2015) The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-beta signaling. Sci Signal 8, ra1.
55. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA & Schwabe RF (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13, 1324–1332.
56. Bian EB, Huang C, Wang H, Chen XX, Zhang L, Lv XW & Li J (2014) Repression of Smad7 mediated by DNMT1 determines hepatic stellate cell activation and liver fibrosis in rats. Toxicol Lett 224, 175–185.
57. Tu X, Zheng X, Li H, Cao Z, Chang H, Luan S, Zhu J, Chen J, Zang Y & Zhang J (2015) MicroRNA-30 protects against carbon tetrachloride-induced liver fibrosis by attenuating transforming growth factor beta signaling in hepatic stellate cells. Toxicol Sci 146, 157–169.
58. Yu F, Guo Y, Chen B, Dong P & Zheng J (2015) MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Invest 95, 781–789.
59. Caja L, Ortiz C, Bertran E, Murillo MM, Miro-Obradors MJ, Palacios E & Fabregat I (2007) Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal 19, 683–694.
60. Sancho P, Bertran E, Caja L, Carmona-Cuenca I, Murillo MM & Fabregat I (2009) The inhibition of the epidermal growth factor (EGF) pathway enhances TGF-beta-induced apoptosis in rat hepatoma cells through inducing oxidative stress coincident with a change in the expression pattern of the NADPH oxidases (NOX) isoforms. Biochim Biophys Acta 1793, 253–263.
61. Caja L, Sancho P, Bertran E & Fabregat I (2011) Dissecting the effect of targeting the epidermal growth factor receptor on TGF-beta-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol 55, 351–358.
62. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H & Mikulits W (2007) PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26, 3395–3405.
63. Carmona-Cuenca I, Herrera B, Ventura JJ, Roncero C, Fernandez M & Fabregat I (2006) EGF blocks NADPH oxidase activation by TGF-beta in fetal rat hepatocytes, impairing oxidative stress, and cell death. J Cell Physiol 207, 322–330.
64. Carmona-Cuenca I, Roncero C, Sancho P, Caja L, Fausto N, Fernandez M & Fabregat I (2008) Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 49, 965–976.
65. Moreno-Càceres J, Caja L, Mainez J, Mayoral R, Martin-Sanz P, Moreno-Vicente R, Del Pozo MA, Dooley S, Egea G & Fabregat I (2014) Caveolin-1 is required for TGF-beta-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17. Cell Death Dis 5, e1326.
66. Tse EY, Ko FC, Tung EK, Chan LK, Lee TK, Ngan ES, Man K, Wong AS, Ng IO & Yam JW (2012) Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol 226, 645–653.
67. Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15, 740–746.
68. Franco DL, Mainez J, Vega S, Sancho P, Murillo MM, de Frutos CA, Del Castillo G, Lopez-Blau C, Fabregat I & Nieto MA (2010) Snail1 suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J Cell Sci 123, 3467–3477.
69. Del Castillo G, Murillo MM, Alvarez-Barrientos A, Bertran E, Fernandez M, Sanchez A & Fabregat I (2006) Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: role of EGF receptor ligands. Exp Cell Res 312, 2860–2871.
70. Moustakas A & Heldin CH (2012) Induction of epithelial-mesenchymal transition by transforming growth factor beta. Semin Cancer Biol 22, 446–454.
71. Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, Law CT, Lee JM, He X, Shi J et al. (2015) MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget 6, 13658–13670.
72. Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL, Jia YL et al. (2015) MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology 62, 801–815.
73. Coulouarn C, Factor VM & Thorgeirsson SS (2008) Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47, 2059–2067.
74. Chen J, Liu WB, Jia WD, Xu GL, Ma JL, Ren Y, Chen H, Sun SN, Huang M & Li JS (2014) Embryonic morphogen nodal is associated with progression and poor prognosis of hepatocellular carcinoma. PLoS One 9, e85840.
75. Dzieran J, Fabian J, Feng T, Coulouarn C, Ilkavets I, Kyselova A, Breuhahn K, Dooley S & Meindl-Beinker NM (2013) Comparative analysis of TGF-beta/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines. PLoS One 8, e72252.
76. Kitisin K, Ganesan N, Tang Y, Jogunoori W, Volpe EA, Kim SS, Katuri V, Kallakury B, Pishvaian M, Albanese C et al. (2007) Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 26, 7103–7110.
77. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J et al. (2008) Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 123, 972–978.
78. Petrocca F, Vecchione A & Croce CM (2008) Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 68, 8191–8194.
79. Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z & Zheng X (2010) miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 10, 354.
80. Coulouarn C & Clement B (2014) Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol 60, 1306–1309.
81. Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, Navarro E, Egea G, Lastra R, Serrano T, Ramos E et al. (2013) Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 58, 2032–2044.
82. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S & Giannelli G (2010) Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 51, 523–534.
83. Calon A, Tauriello DV & Batlle E (2014) TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 25, 15–22.
84. Yi Y, He HW, Wang JX, Cai XY, Li YW, Zhou J, Cheng YF, Jin JJ, Fan J & Qiu SJ (2013) The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGFbeta- and IL-10-dependent manner. J Hepatol 58, 977–983.
85. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y et al. (2012) TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22, 291–303.
86. Calone I & Souchelnytskyi S (2012) Inhibition of TGFbeta signaling and its implications in anticancer treatments. Exp Oncol 34, 9–16.
87. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378–390.
88. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Camma C & Colombo M (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54, 2055–2063.
89. Bruix J, Gores GJ & Mazzaferro V (2014) Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844–855.
90. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A et al. (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The Lancet Oncol 14, 55–63.
91. Bedossa P, Peltier E, Terris B, Franco D & Poynard T (1995) Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21, 760–766.
92. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, Hsieh MY, Lin ZY & Tsai JH (1997) Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 75, 1460–1466.
93. Fransvea E, Angelotti U, Antonaci S & Giannelli G (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47, 1557–1566.
94. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S & Giannelli G (2009) Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50, 1140–1151.
95. Fransvea E, Mazzocca A, Antonaci S & Giannelli G (2009) Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49, 839–850.
96. Giannelli G, Villa E & Lahn M (2014) Transforming growth factor-beta as a therapeutic target in hepatocellular carcinoma. Cancer Res 74, 1890–1894.
97. Fransvea E, Mazzocca A, Santamato A, Azzariti A, Antonaci S & Giannelli G (2011) Kinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol 68, 79–86.
98. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA et al. (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9, 4479–4499.
99. Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabba C & Giannelli G (2013) Differential inhibition of the TGF-beta signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-beta receptor type II. PLoS One 8, e67109.
100. Dituri F, Serio G, Filannino D, Mascolo A, Sacco R, Villa E & Giannelli G (2014) Circulating TGF-beta1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores. Cancer Lett 353, 264–271.
101. Sato Y, Harada K, Itatsu K, Ikeda H, Kakuda Y, Shimomura S, Shan Ren X, Yoneda N, Sasaki M & Nakanuma Y (2010) Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol 177, 141–152.
102. Coulouarn C, Cavard C, Rubbia-Brandt L, Audebourg A, Dumont F, Jacques S, Just PA, Clement B, Gilgenkrantz H, Perret C et al. (2012) Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. Carcinogenesis 33, 1791–1796.
103. Qiao P, Li G, Bi W, Yang L, Yao L & Wu D (2015) microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer 15, 469.